Liu Gordon, Shepherd Jason, Rane Pratik, Zhao Zhongyun, Bailey Hollie, Williams Nathan, Qian Yi
National School of Development, Peking University, Beijing, China.
Adelphi Real World, Macclesfield, UK.
J Drug Assess. 2019 Oct 23;8(1):192-198. doi: 10.1080/21556660.2019.1684926. eCollection 2019.
To describe characteristics of patients with dyslipidemia treated in routine care in China overall and stratified by diabetes and atherosclerotic cardiovascular disease (ASCVD). This study used data from a cross-sectional survey conducted in China in 2017 under the Dyslipidemia Disease Specific Programme (DSP). Each surveyed physician provided information including demographics, dyslipidemia diagnosis and treatment history, lab values on at least 8 patients currently treated for dyslipidemia with oversampling of patients with ASCVD or diabetes mellitus diagnosis at the time of survey. A related patient survey assessed treatment adherence and satisfaction. This study included 195 physicians (40 endocrinologists, 75 internists, 80 cardiologists) who provided data on 1870 patients (852 with diabetes; 1018 patients without diabetes). Among patients with diabetes, 279 had ASCVD and 573 did not (non-ASCVD). In the diabetic population, patients with ASCVD were older (67.3 vs. 62.1 years), more often had caregiver support (34 vs. 14%), and had higher average LDL-C at diagnosis (172.4 vs. 167.4 mg/dL) compared to their non-ASCVD counterparts. Findings were similar for non-diabetic patients (ASCVD: 323 patients; non-ASCVD: 695) patients. In all four subgroups, 46-54% of patients reported low treatment adherence, and fewer than half expressed satisfaction with their cholesterol control, and 2-5% had LDL-C < 70 mg/dL at their most recent assessment. Among patients with dyslipidemia, those with ASCVD had higher LDL-C levels than patients without ASCVD, and many required caregiving. Low levels of treatment adherence, LDL-C control, and patient satisfaction suggest opportunities to improve care for Chinese patients with dyslipidemia.
描述中国常规治疗的血脂异常患者的总体特征,并按糖尿病和动脉粥样硬化性心血管疾病(ASCVD)进行分层。本研究使用了2017年在中国血脂异常疾病专项计划(DSP)下进行的横断面调查数据。每位接受调查的医生提供了包括人口统计学、血脂异常诊断和治疗史、至少8名目前正在接受血脂异常治疗患者的实验室值等信息,调查时对ASCVD或糖尿病诊断患者进行了过度抽样。一项相关的患者调查评估了治疗依从性和满意度。本研究纳入了195名医生(40名内分泌科医生、75名内科医生、80名心脏病专家),他们提供了1870名患者的数据(852名糖尿病患者;1018名非糖尿病患者)。在糖尿病患者中,279名患有ASCVD,573名未患ASCVD(非ASCVD)。在糖尿病患者群体中,与非ASCVD患者相比,ASCVD患者年龄更大(67.3岁对62.1岁),更多人有护理人员支持(34%对14%),诊断时平均LDL-C更高(172.4mg/dL对167.4mg/dL)。非糖尿病患者(ASCVD:323例;非ASCVD:695例)的结果相似。在所有四个亚组中,46 - 54%的患者报告治疗依从性低,不到一半的患者对胆固醇控制表示满意,2 - 5%的患者在最近一次评估时LDL-C < 70mg/dL。在血脂异常患者中,患有ASCVD的患者LDL-C水平高于未患ASCVD的患者,且许多患者需要护理。治疗依从性、LDL-C控制和患者满意度较低表明有机会改善中国血脂异常患者的护理。